Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

Paul B. Chapman, Lawrence Einhorn, Michael L. Meyers, Scott Saxman, Alicia N. Destro, Katherine S. Panageas, Colin B. Begg, Sanjiv S. Agarwala, Lynn M. Schuchter, Marc S. Ernstoff, Alan N. Houghton, John M. Kirkwood

Research output: Contribution to journalArticle

580 Citations (Scopus)

Abstract

Purpose: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients. This study was designed to compare the overall survival time, rate of objective tumor response, and toxicity of the Dartmouth regimen with standard dacarbazine treatment in stage IV melanoma patients. Patients and Methods: In this multicenter phase III trial, 240 patients with measurable stage IV melanoma were randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m2 and cisplatin 25 mg/m2 days 1 to 3, carmustine 150 mg/m2 day 1 every other cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1,000 mg/m2. Treatment was repeated every 3 weeks. Patients were observed for tumor response, survival time, and toxicity. Results: Median survival time from randomization was 7 months; 25% of the patients survived ≥ 1 year. There was no difference in survival time between the two treatment arms when analyzed on an intent-to-treat basis or when only the 231 patients who were both eligible and had received treatment were considered. Tumor response was assessable in 226 patients. The response rate to dacarbazine was 10.2% compared with 18.5% for the Dartmouth regimen (P = .09). Bone marrow suppression, nausea/vomiting, and fatigue were significantly more common in the Dartmouth arm. Conclusion: There was no difference in survival time and only a small, statistically nonsignificant increase in tumor response for stage IV melanoma patients treated with the Dartmouth regimen compared with dacarbazine. Dacarbazine remains the reference standard treatment for stage IV melanoma.

Original languageEnglish (US)
Pages (from-to)2745-2751
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number9
StatePublished - Sep 1999
Externally publishedYes

Fingerprint

Dacarbazine
Multicenter Studies
Melanoma
Carmustine
Survival
Tamoxifen
Neoplasms
Cisplatin
Therapeutics
DBPT regimen
Random Allocation
Nausea
Vomiting
Fatigue
Survival Rate
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chapman, P. B., Einhorn, L., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., ... Kirkwood, J. M. (1999). Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology, 17(9), 2745-2751.

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. / Chapman, Paul B.; Einhorn, Lawrence; Meyers, Michael L.; Saxman, Scott; Destro, Alicia N.; Panageas, Katherine S.; Begg, Colin B.; Agarwala, Sanjiv S.; Schuchter, Lynn M.; Ernstoff, Marc S.; Houghton, Alan N.; Kirkwood, John M.

In: Journal of Clinical Oncology, Vol. 17, No. 9, 09.1999, p. 2745-2751.

Research output: Contribution to journalArticle

Chapman, PB, Einhorn, L, Meyers, ML, Saxman, S, Destro, AN, Panageas, KS, Begg, CB, Agarwala, SS, Schuchter, LM, Ernstoff, MS, Houghton, AN & Kirkwood, JM 1999, 'Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma', Journal of Clinical Oncology, vol. 17, no. 9, pp. 2745-2751.
Chapman, Paul B. ; Einhorn, Lawrence ; Meyers, Michael L. ; Saxman, Scott ; Destro, Alicia N. ; Panageas, Katherine S. ; Begg, Colin B. ; Agarwala, Sanjiv S. ; Schuchter, Lynn M. ; Ernstoff, Marc S. ; Houghton, Alan N. ; Kirkwood, John M. / Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 9. pp. 2745-2751.
@article{8f0b620f2e50456db34d2b298b165e6c,
title = "Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma",
abstract = "Purpose: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40{\%} to 50{\%} of stage IV melanoma patients. This study was designed to compare the overall survival time, rate of objective tumor response, and toxicity of the Dartmouth regimen with standard dacarbazine treatment in stage IV melanoma patients. Patients and Methods: In this multicenter phase III trial, 240 patients with measurable stage IV melanoma were randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m2 and cisplatin 25 mg/m2 days 1 to 3, carmustine 150 mg/m2 day 1 every other cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1,000 mg/m2. Treatment was repeated every 3 weeks. Patients were observed for tumor response, survival time, and toxicity. Results: Median survival time from randomization was 7 months; 25{\%} of the patients survived ≥ 1 year. There was no difference in survival time between the two treatment arms when analyzed on an intent-to-treat basis or when only the 231 patients who were both eligible and had received treatment were considered. Tumor response was assessable in 226 patients. The response rate to dacarbazine was 10.2{\%} compared with 18.5{\%} for the Dartmouth regimen (P = .09). Bone marrow suppression, nausea/vomiting, and fatigue were significantly more common in the Dartmouth arm. Conclusion: There was no difference in survival time and only a small, statistically nonsignificant increase in tumor response for stage IV melanoma patients treated with the Dartmouth regimen compared with dacarbazine. Dacarbazine remains the reference standard treatment for stage IV melanoma.",
author = "Chapman, {Paul B.} and Lawrence Einhorn and Meyers, {Michael L.} and Scott Saxman and Destro, {Alicia N.} and Panageas, {Katherine S.} and Begg, {Colin B.} and Agarwala, {Sanjiv S.} and Schuchter, {Lynn M.} and Ernstoff, {Marc S.} and Houghton, {Alan N.} and Kirkwood, {John M.}",
year = "1999",
month = "9",
language = "English (US)",
volume = "17",
pages = "2745--2751",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

AU - Chapman, Paul B.

AU - Einhorn, Lawrence

AU - Meyers, Michael L.

AU - Saxman, Scott

AU - Destro, Alicia N.

AU - Panageas, Katherine S.

AU - Begg, Colin B.

AU - Agarwala, Sanjiv S.

AU - Schuchter, Lynn M.

AU - Ernstoff, Marc S.

AU - Houghton, Alan N.

AU - Kirkwood, John M.

PY - 1999/9

Y1 - 1999/9

N2 - Purpose: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients. This study was designed to compare the overall survival time, rate of objective tumor response, and toxicity of the Dartmouth regimen with standard dacarbazine treatment in stage IV melanoma patients. Patients and Methods: In this multicenter phase III trial, 240 patients with measurable stage IV melanoma were randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m2 and cisplatin 25 mg/m2 days 1 to 3, carmustine 150 mg/m2 day 1 every other cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1,000 mg/m2. Treatment was repeated every 3 weeks. Patients were observed for tumor response, survival time, and toxicity. Results: Median survival time from randomization was 7 months; 25% of the patients survived ≥ 1 year. There was no difference in survival time between the two treatment arms when analyzed on an intent-to-treat basis or when only the 231 patients who were both eligible and had received treatment were considered. Tumor response was assessable in 226 patients. The response rate to dacarbazine was 10.2% compared with 18.5% for the Dartmouth regimen (P = .09). Bone marrow suppression, nausea/vomiting, and fatigue were significantly more common in the Dartmouth arm. Conclusion: There was no difference in survival time and only a small, statistically nonsignificant increase in tumor response for stage IV melanoma patients treated with the Dartmouth regimen compared with dacarbazine. Dacarbazine remains the reference standard treatment for stage IV melanoma.

AB - Purpose: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients. This study was designed to compare the overall survival time, rate of objective tumor response, and toxicity of the Dartmouth regimen with standard dacarbazine treatment in stage IV melanoma patients. Patients and Methods: In this multicenter phase III trial, 240 patients with measurable stage IV melanoma were randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m2 and cisplatin 25 mg/m2 days 1 to 3, carmustine 150 mg/m2 day 1 every other cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1,000 mg/m2. Treatment was repeated every 3 weeks. Patients were observed for tumor response, survival time, and toxicity. Results: Median survival time from randomization was 7 months; 25% of the patients survived ≥ 1 year. There was no difference in survival time between the two treatment arms when analyzed on an intent-to-treat basis or when only the 231 patients who were both eligible and had received treatment were considered. Tumor response was assessable in 226 patients. The response rate to dacarbazine was 10.2% compared with 18.5% for the Dartmouth regimen (P = .09). Bone marrow suppression, nausea/vomiting, and fatigue were significantly more common in the Dartmouth arm. Conclusion: There was no difference in survival time and only a small, statistically nonsignificant increase in tumor response for stage IV melanoma patients treated with the Dartmouth regimen compared with dacarbazine. Dacarbazine remains the reference standard treatment for stage IV melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0032858487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032858487&partnerID=8YFLogxK

M3 - Article

C2 - 10561349

AN - SCOPUS:0032858487

VL - 17

SP - 2745

EP - 2751

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -